Kristin Brooks03.25.14
Cytovance Biologics, Inc. is extending its manufacturing agreement with Precision Biologics, Inc. for additional cGMP manufacturing services to support ongoing Phase II trials of NEO-102, a therapeutic drug candidate for pancreatic and colorectal cancers. Precision had previously contracted Cytovance as its CMO to provide technology transfer and cGMP manufacturing services.
"With this agreement, Precision Biologics is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance," said Dr. Albine Martin, chief operating officer of Precision Biologics, Inc. "Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers."
"Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics," said Darren Head, president and chief executive officer of Cytovance Biologics, Inc. "We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program."
